Asia Pacific to Report Fastest CAGR 8.7% : Non-Small Cell Lung Cancer Therapeutics Market Will Be Valued at $4.9 Billion in 2022
Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated...
View full press release